- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04039802
Single-stage Surgery Using the BHX Implant
Single-stage Bone-anchored Hearing Implant Surgery in the Pediatric Population Using the BHX Implant
Study Overview
Status
Intervention / Treatment
Detailed Description
General description:
A prospective comparative study with historical control group will be performed.The test group will consist of 22 children aged 4-9 years old who are found to be suitable candidates for treatment with a BAHI (BHX implant and abutment). The control group consists of approximately 50 children, aged 4-9 years old, who already underwent insertion with a wide diameter implant between 2012 and 2018. In the test group, BAHI insertion will be performed using single-stage surgery. Patients in the control group already underwent BAHI insertion using two-stage surgery.
Recruitment and consent:
All children planned for implantation with bone-anchored hearing implants will be screened for inclusion in the present study. Patients who meet the inclusion criteria will be approached for participation by their ENT-specialist, after patients' and parents/caretakers' approval they will be informed and screened for participation by one of the researchers. The study protocol will be discussed with the potential study participant and his/her parents/caretakers by the researcher. The potential study participant and his/her parents/caretakers will be given/sent the Informed Consent Form to read. Potential study participants will be encouraged to discuss the study with family members and personal physician(s) before deciding whether to participate in the study. Patients and their parents/caretakers have 14 days to consider their decision. In order to participate in the study, both parents/caretakers need to sign the informed consent form.
Data handling:
Data captured will be recorded in Castor using electronic Case Report Forms (eCRFs). All data, patient and product related, must be accurately recorded in the eCRF by the delegated site staff. All users of the Castor system have personal, password protected accounts allowing tracking of all data entry in the system. Data management and data cleaning will be performed in the eCRF using the queries function to ensure traceability of all data entry and changes by the assigned data manager. Data including patient identifying information (i.e. name, initials, birth date) will be stored on a secured network drive using a code. Only the investigator who has the code can correlate the data with the patient's name and date of birth. It is the responsibility of the investigator to make sure that patient identification listings with patient code and identity are kept. Raw measurement data and other data such as historical information will be storedin the patient file, since data may be partly acquired and/or evaluated during standard patient care to limit the amount of extra procedures and hospital visits. For data analyses, data will be exported and stored in a digital research environment, separate from the key to the code. After completion of the study data collection and final monitoring visit, the electronic database will be locked and exported to SPSS format, which will be archived for 15 years after completion of the study. The coded study data will be archived separately from the key to the subject code in a secured digital research environment, also for a period of 15 years.
Reporting (severe) adverse events:
The investigator will report the Severe Adverse Events (SAEs) through the web portal ToetsingOnline to the accredited Medical Ethical Committee (METC) that approved the protocol, within 7 days of first knowledge for SAEs that result in death or are life threatening followed by a period of maximum of 8 days to complete the initial preliminary report. All other SAEs will be reported within a period of maximum 15 days after the investigator has first knowledge of the serious adverse events.
Device deficiency:
Inadequacy of an investigational medical device related to its identity, quality, durability, reliability, safety or performance. This may include malfunctions, use error, or inadequacy in the information supplied by the manufacturer. Device deficiency's will be logged together with an assessment by the investigator and reported to the manufacturer where applicable.
Follow-up of adverse events:
All Adverse Events (AEs) will be followed until they have abated, or until a stable situation has been reached. Depending on the event, follow up may require additional tests or medical procedures as indicated, and/or referral to the general physician or a medical specialist. SAEs need to be reported until the end of study within the Netherlands, as defined in the protocol.
Monitoring and Quality Assurance:
In accordance with the guidelines of the 'Dutch Federation of university medical centers' (NFU) for monitoring of studies with negligible risk, a qualified monitor of another department of the Radboudumc, who is not part of the research team of this study, will be appointed. 28% of informed consents, 10% of inclusion and exclusion criteria (and three subjects who were enrolled first), 10% source data verification, reported SAEs and 10% of participants with regard to missed SAEs will be monitored.
Statistical analysis:
The main analyses will be the comparison between the test group, in which single-stage surgery is performed and the control group undergoing two-stage surgery.
Concerning the primary outcome, the proportions of implant loss in the test and control group will be compared using an exact binominal test and a one tailed confidence interval of 95%.
Secondary outcome measures will be compared between groups using the unpaired t-test (normally distributed data or Mann-Whitney U tests (not normally distributed data) for continuous variables, Mantel Haenszel chi-square test for ordered categorical variables, Fisher's exact test for dichotomous variables and Chi-square test for non-ordered categorical variables. If significant differences are found for baseline variables between the test group and the control group a complementary analysis between the two groups will be performed with adjustment for these variables.
Handling of missing data for secondary and tertiary endpoints (especially applicable for control group data), depends on the reason why this data is missing and on the amount of missing data. Therefore decisions on handling of missing data will be made after all data is collected.
All tests will be performed using a confidence interval of 95% and a significance level of 0.05
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Caspers
- Phone Number: 00111111111
- Email: xx.xx@radboudumc.nl
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6500HB
- Recruiting
- Radboudumc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria test group:
- Age 4-9 years
- Indication for percutaneous bone-anchored hearing implant surgery with a BI300 implant
- Insertion using the linear incision technique
Inclusion criteria control group:
- Children who underwent implantation of a wide diameter implant using two- stage surgery between 2012 and 2018 at the Radboudumc
- Age 4-9 at the time of surgery
- Linear incision technique was used during surgery
Exclusion Criteria test group:
- Inability to show up at all follow-up visits
- Patients undergoing re-implantation
- Diseases, syndromes or treatments known to compromise the bone quality at the implant site, e.g. radiotherapy, osteoporosis, diabetes mellitus.
- Insufficient bone thickness ≤1mm, since conversion to two-stage surgery will be advocated
Exclusion Criteria control group
- Follow-up duration less than 1 year.
- Diseases, syndromes or treatments known to compromise the bone quality at the implant site, e.g. radiotherapy, osteoporosis, diabetes mellitus (at moment of implantation)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Test
In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure.
The implant and abutment will be placed in one surgery
|
In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure.
The implant and abutment will be placed in one surgery.
|
Control
Historical control group, these patients already underwent BAHI insertion using two-stage surgery.
The implant and abutment were inserted in two different procedures
|
Two-stage surgery has already been performed, data will therefore be retrospectively collected
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Implant loss
Time Frame: 1 year
|
The number of lost implants
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to loading
Time Frame: through study completion, an average of 1 year
|
Time from first surgery until loading of sound processor
|
through study completion, an average of 1 year
|
Soft-tissue status according to Holgers scale
Time Frame: 1 year
|
The Holgers scale is a worldwide used soft tissue assessment scale for percutaneous implants for BCDs. The degree of soft tissue reactions is classified as follows27: 0 = No irritation
|
1 year
|
Soft-tissue status according to IPS
Time Frame: 1 year
|
The IPS scale is a relatively new consistent, uniform, and easy assessment scale for both percutaneous and transcutaneous implants for BCDs.28 For percutaneous implants, the IPS-scale comprising three parts: inflammation, pain, and skin height, with higher scores reflecting more severe complication. It assesses the following characteristics:
|
1 year
|
Duration of surgery
Time Frame: through study completion, an average of 1 year
|
In test group duration of single-stage surgery.
In the control group duration of first and second surgery together
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Collaborators
Publications and helpful links
General Publications
- Saliba I, Froehlich P, Bouhabel S. One-stage vs. two-stage BAHA implantation in a pediatric population. Int J Pediatr Otorhinolaryngol. 2012 Dec;76(12):1814-8. doi: 10.1016/j.ijporl.2012.09.007. Epub 2012 Sep 23.
- Kohan D, Morris LG, Romo T 3rd. Single-stage BAHA implantation in adults and children: is it safe? Otolaryngol Head Neck Surg. 2008 May;138(5):662-6. doi: 10.1016/j.otohns.2007.12.019.
- Ali S, Hadoura L, Carmichael A, Geddes NK. Bone-anchored hearing aid A single-stage procedure in children. Int J Pediatr Otorhinolaryngol. 2009 Aug;73(8):1076-9. doi: 10.1016/j.ijporl.2009.03.028. Epub 2009 May 26.
- Marsella P, Scorpecci A, D'Eredita R, Della Volpe A, Malerba P. Stability of osseointegrated bone conduction systems in children: a pilot study. Otol Neurotol. 2012 Jul;33(5):797-803. doi: 10.1097/MAO.0b013e318255dd73.
- de Wolf MJ, Hol MK, Huygen PL, Mylanus EA, Cremers CW. Nijmegen results with application of a bone-anchored hearing aid in children: simplified surgical technique. Ann Otol Rhinol Laryngol. 2008 Nov;117(11):805-14. doi: 10.1177/000348940811701103.
- Mazita A, Fazlina WH, Abdullah A, Goh BS, Saim L. Hearing rehabilitation in congenital canal atresia. Singapore Med J. 2009 Nov;50(11):1072-6.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-5408
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hearing Impaired Children
-
Assiut UniversityUnknownHearing Impaired Children
-
Assiut UniversityUnknownHearing Impaired Children
-
Sara Magdy IbrahimAlexandria UniversityCompletedHearing Impaired ChildrenEgypt
-
Amira Mohmed Ahmed BakrAssiut UniversityUnknownHearing Impaired Children
-
The Bionics Institute of AustraliaNot yet recruitingHearing Impaired Children
-
Riphah International UniversityCompletedHEARING IMPAIRED CHILDRENPakistan
-
University Hospital, GhentUniversitaire Ziekenhuizen KU Leuven; Jessa Hospital; Queen Fabiola Children's... and other collaboratorsCompletedVestibular Disorder | Hearing Impaired ChildrenBelgium
-
Bezmialem Vakif UniversityNuh Naci Yazgan UniversityRecruitingRespiration | Functional Capacity | Hearing Impaired Children | Endurance | Core StabilizationTurkey
-
University of OuluUniversity of Helsinki; Tampere UniversityRecruitingHearing Impairment | Hearing Impaired ChildrenFinland
Clinical Trials on Two-stage surgery
-
Radboud University Medical CenterCochlear Bone Anchored SolutionsRecruitingHearing Impaired Children | Hearing Impairment, ConductiveNetherlands
-
Erzincan UniversityMode Medical Implant ManufacturerNot yet recruitingDiabetes Mellitus | Dental Implant Surgical Techniques | Short Dental Implants
-
OrthoCarolina Research Institute, Inc.University of Iowa; The Cleveland Clinic; Emory University; University of Southern... and other collaboratorsActive, not recruitingSurgical Site InfectionUnited States
-
VNU University of Medicine and PharmacyCompletedBone ResorptionVietnam
-
Odense University HospitalRegion of Southern Denmark; Odense Patient Data Explorative NetworkRecruitingPeriprosthetic Knee InfectionDenmark
-
Unity Health TorontoUnknownArthroplasty Complications | Total Hip Replacement
-
McMaster UniversityMcMaster Surgical AssociatesRecruitingCryptorchidismCanada
-
NorthShore University HealthSystemTerminatedEsophageal CancerUnited States
-
Professor Fernando Figueira Integral Medicine InstituteUniversity of Sao PauloCompletedDevelopmental Disabilities | Cleft Palate | Cleft Lip | Unilateral Cleft Lip and Palate | Restricted Language Development
-
Royal Devon and Exeter NHS Foundation TrustNottingham University Hospitals NHS Trust; University of Exeter; Wrightington... and other collaboratorsCompletedArthroplasty, Replacement, KneeUnited Kingdom